Sector News

PhRMA finally launches campaign to discuss drug costs

July 17, 2017
Life sciences

Probably one of the last things the pharma industry wants to talk about today is the cost of drugs. Or does it? Industry trade group PhRMA has launched new advertising meant to tackle the issue head-on.

The national campaign, “Let’s Talk About Cost,” is a specific print, radio, digital and social effort, but that moniker will also now serve as the branded umbrella for all of PhRMA’s cost and value communications that have been going on for years. That includes Share the Savings discussions around rebates and discounts, and the Value Collaborative effort to engage leaders on reform issues.

“We’ve been actively making sure that we are putting the cost and value of medicines in perspective for many years now. Too often though, so many of the conversations still focus on costs and spending from 2014, which we know was an anomaly year,” Holly Campbell, senior director of communications at PhRMA, said in an interview, referencing the year that saw the introduction of expensive hepatitis C cures. “Unfortunately, those are still the points most often used in conversations. We need to make sure the new facts and trends moving forward on medicine costs and spending are reflected.”

The initial print ad, which ran last week in The Wall Street Journal, was a series of four questions, including “Why am I paying more than my insurer for my medicine?” and “Who decides what I pay for my medicine?” The ad redirects readers to the custom website at phrma.org/letstalkaboutcost for the answers.

The other part of the cost effort is acknowledging the struggle some patients face to pay for medicines they need and help them to find answers, Campbell said. The campaign will also highlight the online resource Partnership for Prescription Assistance, a PhRMA kind of clearinghouse website where patients can get information about reduced price or free prescription medication programs through pharma companies and third-party providers.

The new cost savings advertising umbrella works in conjunction with PhRMA’s broader Go Boldly branding initiative to strengthen the pharma industry’s reputation. The body has spent millions on that science-focused effort, which it unveiled in January, but critics have questioned whether the industry could really salvage its battered reputation without even mentioning the controversial cost issue.

By Beth Snyder Bulik

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.